CN102159239A - 针对hpv的疫苗 - Google Patents

针对hpv的疫苗 Download PDF

Info

Publication number
CN102159239A
CN102159239A CN200980135875XA CN200980135875A CN102159239A CN 102159239 A CN102159239 A CN 102159239A CN 200980135875X A CN200980135875X A CN 200980135875XA CN 200980135875 A CN200980135875 A CN 200980135875A CN 102159239 A CN102159239 A CN 102159239A
Authority
CN
China
Prior art keywords
hpv
vaccine
dose
purposes
vlp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200980135875XA
Other languages
English (en)
Chinese (zh)
Inventor
多米尼克·德坎普斯
桑德拉·詹尼尼
尼古拉斯·勒克伦尼尔
琼·斯蒂芬尼
马蒂尼·A·C·韦坦多尔夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of CN102159239A publication Critical patent/CN102159239A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN200980135875XA 2008-07-31 2009-07-29 针对hpv的疫苗 Pending CN102159239A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8510108P 2008-07-31 2008-07-31
US61/085,101 2008-07-31
US17656109P 2009-05-08 2009-05-08
US61/176,561 2009-05-08
PCT/EP2009/059820 WO2010012780A1 (en) 2008-07-31 2009-07-29 Vaccine against hpv

Publications (1)

Publication Number Publication Date
CN102159239A true CN102159239A (zh) 2011-08-17

Family

ID=41139260

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980135875XA Pending CN102159239A (zh) 2008-07-31 2009-07-29 针对hpv的疫苗

Country Status (26)

Country Link
US (1) US20110189229A1 (OSRAM)
EP (1) EP2318042B1 (OSRAM)
JP (1) JP6022159B2 (OSRAM)
KR (1) KR20110053340A (OSRAM)
CN (1) CN102159239A (OSRAM)
AU (1) AU2009275909A1 (OSRAM)
BR (1) BRPI0916732B1 (OSRAM)
CA (1) CA2732436C (OSRAM)
CO (1) CO6341567A2 (OSRAM)
DK (1) DK2318042T3 (OSRAM)
DO (1) DOP2011000031A (OSRAM)
EA (1) EA201170264A1 (OSRAM)
ES (1) ES2519490T3 (OSRAM)
HR (1) HRP20141063T1 (OSRAM)
IL (1) IL210977A0 (OSRAM)
MA (1) MA32554B1 (OSRAM)
MX (1) MX2011001218A (OSRAM)
NZ (1) NZ590919A (OSRAM)
PE (1) PE20110327A1 (OSRAM)
PL (1) PL2318042T3 (OSRAM)
PT (1) PT2318042E (OSRAM)
RS (1) RS53607B1 (OSRAM)
SI (1) SI2318042T1 (OSRAM)
SM (1) SMT201400170B (OSRAM)
WO (1) WO2010012780A1 (OSRAM)
ZA (1) ZA201100889B (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120087937A1 (en) 2009-06-25 2012-04-12 Brigitte Desiree Alberte Colau Novel compositions
CN102178944A (zh) * 2010-09-17 2011-09-14 大连雅立峰生物制药有限公司 人乳头瘤病毒16和18型l1蛋白在昆虫细胞中的表达及应用
CN102229660B (zh) 2011-05-25 2015-04-22 厦门大学 截短的人乳头瘤病毒33型l1蛋白
KR101559622B1 (ko) 2012-07-30 2015-10-13 중앙대학교 산학협력단 인유두종바이러스 바이러스 유사입자의 고효율 정제방법
MA40624A (fr) * 2014-09-11 2016-03-17 Cadila Healthcare Ltd Antigènes supérieurs du papillomavirus présentant des propriétés immunologiques supérieures et vaccin les contenant
US10063211B2 (en) 2016-02-03 2018-08-28 Qualcomm Incorporated Compact bypass and decoupling structure for millimeter-wave circuits
RU2628693C1 (ru) * 2016-11-10 2017-08-21 федеральное государственное бюджетное учреждение "Федеральный научно-исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации (ФГБУ "ФНИЦЭМ им. Н.Ф. Гамалеи" Минздрава России) РЕКОМБИНАНТНЫЙ ГЕН L1HPV16, РЕКОМБИНАНТНАЯ ПЛАЗМИДА pQE-L1/16, БЕЛОК L1HPV16 И ИХ ПРИМЕНЕНИЕ
US20210302427A1 (en) * 2020-03-31 2021-09-30 Shuhari Group, LLC Secure Immunity Information Transmission System And Network
WO2025147639A1 (en) * 2024-01-04 2025-07-10 Cyanvac Llc Improved formulation providing increased stability for vaccines composition

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1618465A (zh) * 1999-09-07 2005-05-25 史密丝克莱恩比彻姆生物有限公司 联合疫苗组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005089164A2 (en) * 2003-12-31 2005-09-29 Pharmexa Inc. Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
PL1758609T3 (pl) * 2004-06-16 2013-02-28 Glaxosmithkline Biologicals Sa Szczepionka przeciw HPV16 i HPV18 oraz co najmniej jednemu HPV innego typu wybranemu spośród HPV 31, 45 lub 52
US7758866B2 (en) * 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
KR20080005585A (ko) * 2005-04-26 2008-01-14 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1618465A (zh) * 1999-09-07 2005-05-25 史密丝克莱恩比彻姆生物有限公司 联合疫苗组合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HERRERO R. ET AL: "Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica.", 《VACCINE》 *

Also Published As

Publication number Publication date
US20110189229A1 (en) 2011-08-04
ES2519490T3 (es) 2014-11-07
DK2318042T3 (da) 2014-11-10
CA2732436A1 (en) 2010-02-04
SMT201400170B (it) 2015-01-15
MA32554B1 (fr) 2011-08-01
CO6341567A2 (es) 2011-11-21
WO2010012780A1 (en) 2010-02-04
JP2011529475A (ja) 2011-12-08
MX2011001218A (es) 2011-03-15
PL2318042T3 (pl) 2015-02-27
IL210977A0 (en) 2011-04-28
EA201170264A1 (ru) 2011-08-30
DOP2011000031A (es) 2011-02-28
CA2732436C (en) 2018-01-16
BRPI0916732B1 (pt) 2021-06-29
PE20110327A1 (es) 2011-06-29
EP2318042B1 (en) 2014-08-20
AU2009275909A1 (en) 2010-02-04
NZ590919A (en) 2012-10-26
JP6022159B2 (ja) 2016-11-09
ZA201100889B (en) 2012-04-25
BRPI0916732A2 (pt) 2017-01-31
PT2318042E (pt) 2014-11-05
HRP20141063T1 (hr) 2015-01-02
KR20110053340A (ko) 2011-05-20
SI2318042T1 (sl) 2014-12-31
EP2318042A1 (en) 2011-05-11
RS53607B1 (sr) 2015-04-30

Similar Documents

Publication Publication Date Title
CN100528226C (zh) 人乳头瘤病毒的病毒样颗粒
JP4546092B2 (ja) ワクチン
EP2318042B1 (en) Vaccine against hpv
MX2011013744A (es) Construcciones novedosas de proteinas del virus de papiloma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv.
JP5475939B2 (ja) Ｈｐｖ−１６およびｈｐｖ−１８ｌ１ｖｌｐワクチン
JP2012102132A (ja) Ｈｐｖ１６およびｈｐｖ１８ならびにｈｐｖ３１、４５または５２から選ばれる少なくとも１つの別のｈｐｖ型に対するワクチン
WO2004052395A1 (en) L2-peptide of the human papillomavirus associated with virus-like particles
EP1758609B1 (en) Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52
CN100418577C (zh) Hpv-16和hpv-18l1vlp疫苗
US7758866B2 (en) Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
CN101217975A (zh) 疫苗

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20110817